Clinical trials: Dysthyroid Orbitopathy
Graves Orbitopathy, Hyperthyroidism
Development of a Non-Invasive Prognostic Test for Graves Orbitopathy
The aim of this research project is to develop a non-invasive, simple, robust, and sensitive prognostic test that can identify hyperthyroidism patients who are at risk of developing Graves' Orbitopathy.
- Trial name
- GoPro (NCT07472062)
- Testing
- Schirmer's test
- Where
- Belgium
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
Graves' Disease
Randomized Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy
OBJECTIVES: I. Evaluate the effects of 20 Gy of external-beam radiotherapy to 1 orbit vs. the untreated orbit at 3 and 6 months after therapy in patients with Graves' ophthalmopathy. II.
- Trial name
- NCT00004660
- Testing
- Radiotherapy
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Thyroid Eye Disease
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid Eye Disease (TED).
- Trial name
- REVEAL-1 (NCT06625411)
- Testing
- VRDN-003
- Where
- 48 sites in United States, Germany and 3 more
- Volunteers
- 132 people
- Sponsor
- Viridian Therapeutics, Inc.
Thyroid Eye Disease, Graves' Orbitopathy
Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease
This is an expanded access protocol intended to provide access to teprotumumab for the treatment of up to 60 patients in the United States with active moderate to severe thyroid eye disease where there is no comparable or…
- Trial name
- EAP (NCT04040894)
- Testing
- Teprotumumab
- Where
- 8 sites in United States
- Sponsor
- Amgen
Thyroid Eye Disease
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period.
- Trial name
- NCT06248619
- Testing
- Teprotumumab
- Where
- 38 sites in United States, Argentina and 9 more
- Volunteers
- 89 people
- Sponsor
- Amgen
Graves Disease, Graves Ophthalmopathy
Liver Function After Intravenous Methylprednisolone Administration
Graves' orbitopathy (GO) is a characterized by orbital soft tissue inflammation and oedema associated with glycosaminoglycan deposition and fibrosis. The most frequent cause is Graves' disease.
- Conditions
- Graves Disease, Graves Ophthalmopathy, Liver Diseases, Liver Failure
- Trial name
- NCT03667157
- Testing
- every week IVMP therapy, very high doses IVMP therapy
- Volunteers
- 68 people
- Sponsor
- Medical University of Warsaw
Thyroid Eye Disease
Study of ZB001 in Chinese Patients With Thyroid Eye Disease
The investigational drug, ZB001 is a humanized IgG1κ monoclonal antibody targeting human IGF-1R. The study is designed to evaluate the efficacy, safety, tolerability, and pharmacokinetics（PK）/pharmacodynamics (PD) profile of…
- Trial name
- NCT05776121
- Testing
- ZB001 for injection
- Where
- 9 sites in China
- Volunteers
- 17 people
- Sponsor
- Zenas BioPharma (USA), LLC
Thyroid Eye Disease
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
- Trial name
- NCT05517421
- Testing
- Batoclimab
- Where
- 93 sites in United States, Canada and 7 more
- Volunteers
- 114 people
- Sponsor
- Immunovant Sciences GmbH
Graves' Ophthalmopathy
Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy and in Normal People
Find if the retinal function is affected in both the nonsevere and the severe stage of Graves' ophthalmopathy (GO) by comparing the retinal oxygen saturation of GO patients with that of normal people.
- Trial name
- NCT02290704
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Thyroid Eye Disease
TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study
This is a double-masked, randomized, parallel-assignment, multicenter trial examining the safety and tolerability of teprotumumab in the treatment of Thyroid Eye Disease (TED) in adult participants.
- Trial name
- NCT05002998
- Testing
- Teprotumumab
- Where
- 28 sites in United States, France and 4 more
- Volunteers
- 313 people
- Sponsor
- Amgen
Graves' Orbitopathy
A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy
Graves' disease (GD) is the most frequent cause of hyperthyroidism in iodine sufficient countries and Graves' orbitopathy (GO) is its most common extrathyroidal manifestation.
- Trial name
- ABLAGO (NCT04776993)
- Testing
- Methimazole, Radioiodine or thyroidectomy
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- University of Pisa
Graves´ Disease
Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study)
AGO study - adjuvant treatment, with NSAID, of endocrine ophthalmopathy in Graves´ disease Background - Already at diagnosis of Graves disease approximately 98% of the patients have morphological changes of the retrobulbar tissue…
- Trial name
- aGO (NCT01458600)
- Testing
- Diclofenac, Methimazole, L-thyroxin
- Where
- 3 sites in Sweden
- Volunteers
- 65 people
- Sponsor
- Mikael Lantz
Graves Ophthalmopathy
Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction
Currently there are few therapeutic options for the treatment of lid retraction secondary to thyroid orbitopathy (TO) during the active stages of the disease.
- Trial name
- NCT01272414
- Testing
- Botulinum Toxin Type A, Saline injection
- Where
- Canada
- Sponsor
- University of Toronto
Thyroid Eye Disease
Disappearance of Graves' Orbitopathy
There is a general belief among physicians involved with Graves' orbitopathy (GO) that this syndrome is somehow "chronic", namely that the patient's eyes do not return the way they were before GO appeared.
- Trial name
- DISGO (NCT03103607)
- Testing
- Ophthalmological evaluation, Questionnaire
- Volunteers
- 99 people
- Sponsor
- University of Pisa
Basedow Disease
Describe the Progression of Inflammatory Orbitopathy and the Biological Progression of Patients Receiving Second-line Treatment
Describe the progression of inflammatory orbitopathy and the biological progression of patients receiving second-line treatment (immunosuppressants, radiotherapy, or biotherapy).
- Trial name
- HZN-IIT (NCT07117981)
- Where
- 9 sites in France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Graves Ophthalmopathy
Genetics and Epigenetics of Graves' Orbitopathy
Graves' orbitopathy (GO) is an autoimmune disease persisting when immunosuppression is achieved. Orbital fibroblasts from GO patients display peculiar phenotypes even if not exposed to autoimmunity, possibly reflecting genetic or…
- Trial name
- GeneGO (NCT04488406)
- Testing
- No Intervention
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- University of Pisa
Thyroid Eye Disease (TED), Graves Ophthalmopathy
Prospective Observational Study of Smartphone-Based AI Self-Monitoring During Non-Surgical Treatment for Thyroid Eye Disease (THYROSCOPE)
This prospective observational study evaluates the feasibility and clinical utility of a smartphone-based artificial intelligence (AI) self-monitoring system in adults with thyroid eye disease (TED) undergoing non-surgical…
- Conditions
- Thyroid Eye Disease (TED), Graves Ophthalmopathy, Thyroid Associated Ophthalmopathies
- Trial name
- THYROSCOPE-TED (NCT07623993)
- Testing
- Smartphone-based AI self-monitoring application (Glandy CAS/EXO/LID)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- THYROSCOPE INC.
Orbitopathy, Graves, Thyroid Eye Disease
Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)
The aim of this study is to evaluate the efficacy and safety of Tocilizumab as second/third line treatment in patients with Active Moderate-to-Severe Corticosteroid-Resistant Thyroid Eye Disease.
- Conditions
- Orbitopathy, Graves, Thyroid Eye Disease, Ophthalmopathy
- Trial name
- NCT06367517
- Testing
- Tocilizumab
- Where
- Poland
- Volunteers
- 32 people
- Sponsor
- Medical University of Warsaw
Graves Ophthalmopathy
Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy
The purpose of this study is to examine the effects of Azithromycin (a macrolide class antibiotic), given three times weekly, for patients with active moderate-severe, non sight-threatening, Graves Orbitopathy.
- Trial name
- NCT01379196
- Testing
- Azithromycin
- Sponsor
- Rabin Medical Center
Thyroid Ophthalmopathy
A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease
Primary Objective: To preliminarily evaluate the efficacy of the treatment regimen of HBM9161 680 mg administered subcutaneously weekly and sequentially every other week for 12 weeks in Chinese patients with active moderate to…
- Trial name
- NCT05015127
- Testing
- HBM9161 680 mg qw by q2w from week 13, HBM9161 680 mg qw by q2w from week 7
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Harbour BioMed (Guangzhou) Co. Ltd.